Modelling the cost-effectiveness of cervical cancer screening with HPV self-sampling and molecular triage for women aged 60–69 years

Background Since 2022, self-sampling has been recommended in Sweden’s cervical screening program. Despite still being used primarily for long-term non-attendees, its expected increase in use raises interest in molecular triage methods applicable to self-collected samples. Postmenopausal women face s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Discover. Oncology Ročník 16; číslo 1; s. 805 - 12
Hlavní autoři: Fridljung, Jasmine, Bergengren, Lovisa, Ryen, Linda, Lillsunde Larsson, Gabriella
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York Springer US 18.05.2025
Springer Nature B.V
Springer
Témata:
Age groups
Cancer Research
Cellular biology
Cervical cancer
Cervical screening
Cost analysis
Cost-effectiveness
DNA methylation
Economic evaluation
Genotyping
HPV
HSIL
Human papillomavirus
Internal Medicine
Medical screening
Medicine
Medicine & Public Health
Methylation
Molecular Medicine
Oncology
Radiotherapy
Self-sampling
Surgical Oncology
Vagina
Womens health
Sweden
Self-sampling
Genotyping
Economic evaluation
Cervical screening
Methylation
Cost-effectiveness
HPV
HSIL
ISSN:2730-6011, 2730-6011
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background Since 2022, self-sampling has been recommended in Sweden’s cervical screening program. Despite still being used primarily for long-term non-attendees, its expected increase in use raises interest in molecular triage methods applicable to self-collected samples. Postmenopausal women face screening challenges due to physiological changes, making this group particularly relevant for evaluating alternative strategies. This study models the cost-effectiveness of different sampling and triage methods in identifying histological high-grade squamous intraepithelial lesions (HSIL) in women aged 60–69 years. Methods Using real-world data, this study compares the cost-effectiveness of currently implemented strategy based on professional HPV sampling and combination triage with genotyping and cytology, with modelled strategies based on self-sampling and various molecular triage. The comparison evaluates healthcare resource use and the number of identified histological HSIL cases. The analysis focuses on a single screening cycle, re-testing of invalid samples or screening-positive/triage-negative women are not addressed. Results Screening with molecular triage either leads to decreases in effect, i.e. fewer histological HSIL identified, or significant cost increases due to higher rate of HPV-positive screening samples and higher number of colposcopy follow-ups. Conclusions Molecular triage, whether used with self-sampling or professional sampling, does not appear cost-effective for identifying HSIL in this age group compared to the current screening strategy.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2730-6011
2730-6011
DOI:10.1007/s12672-025-02432-3